Bluebird Bio Stock Performance
| BLUE Stock | USD 7.91 0.36 4.77% |
On a scale of 0 to 100, Bluebird Bio holds a performance score of 3. The firm shows a Beta (market volatility) of -1.98, which signifies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Bluebird Bio are expected to decrease by larger amounts. On the other hand, during market turmoil, Bluebird Bio is expected to outperform it. Please check Bluebird Bio's semi variance, and the relationship between the maximum drawdown and accumulation distribution , to make a quick decision on whether Bluebird Bio's price patterns will revert.
Risk-Adjusted Performance
3 of 100
Weak | Strong |
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Bluebird bio are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of rather unfluctuating basic indicators, Bluebird Bio exhibited solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 4.77 | Five Day Return 0.25 | Year To Date Return (8.98) | Ten Year Return (99.33) | All Time Return (97.73) |
Last Split Factor 1:20 | Last Split Date 2024-12-13 |
1 | bluebird bio Promising Gene Editing Stock with FDA-Approved Therapies - Yahoo Finance | 10/31/2024 |
2 | bluebird bio Reports Third Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance | 11/14/2024 |
3 | Ionpath Launches MIBIslide Blue Transforming Multi-Omics Imaging with Breakthrough Slide Technology | 12/03/2024 |
4 | Disposition of 2824 shares by Colvin Richard A of Bluebird Bio at 0.4173 subject to Rule 16b-3 | 12/10/2024 |
5 | Acquisition by Paulson Richard A. of 24900 shares of Bluebird Bio subject to Rule 16b-3 | 12/12/2024 |
6 | bluebird bio, Inc. Short Interest Update | 12/16/2024 |
7 | Bluebird Bio Shares Surge Amid Market Activity | 12/24/2024 |
8 | bluebird bios SWOT analysis gene therapy stock faces cash crunch amid launch | 12/31/2024 |
9 | Disposition of 140 shares by Andrew Obenshain of Bluebird Bio at 9.24 subject to Rule 16b-3 | 01/06/2025 |
10 | RBC Capital cuts Bluebird Bio stock target to 8 from 80 - Investing.com | 01/07/2025 |
11 | Disposition of 4526 shares by Krawtschuk Christopher of Bluebird Bio at 4.5155 subject to Rule 16b-3 | 01/10/2025 |
12 | LE RAPPORT BLUE SHIFT DARTHUR D. LITTLE EXPLORE LIMPACT DE LIA SUR LA TRANSFORMATION DE LA RECHERCHE, DU DVELOPPEMENT ET DE LINNOVATION. | 01/15/2025 |
| Begin Period Cash Flow | 158.4 M |
Bluebird |
Bluebird Bio Relative Risk vs. Return Landscape
If you would invest 926.00 in Bluebird bio on November 2, 2024 and sell it today you would lose (135.00) from holding Bluebird bio or give up 14.58% of portfolio value over 90 days. Bluebird bio is currently generating 0.7488% in daily expected returns and assumes 16.5115% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Bluebird, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Bluebird Bio Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Bluebird Bio's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Bluebird bio, and traders can use it to determine the average amount a Bluebird Bio's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0454
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | BLUE | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 16.51 actual daily | 96 96% of assets are less volatile |
Expected Return
| 0.75 actual daily | 14 86% of assets have higher returns |
Risk-Adjusted Return
| 0.05 actual daily | 3 97% of assets perform better |
Based on monthly moving average Bluebird Bio is performing at about 3% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Bluebird Bio by adding it to a well-diversified portfolio.
Bluebird Bio Fundamentals Growth
Bluebird Stock prices reflect investors' perceptions of the future prospects and financial health of Bluebird Bio, and Bluebird Bio fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Bluebird Stock performance.
| Return On Equity | -1.87 | ||||
| Return On Asset | -0.36 | ||||
| Operating Margin | (5.49) % | ||||
| Current Valuation | 371.15 M | ||||
| Shares Outstanding | 9.72 M | ||||
| Price To Earning | (19.32) X | ||||
| Price To Book | 0.73 X | ||||
| Price To Sales | 1.40 X | ||||
| Revenue | 29.5 M | ||||
| Gross Profit | (21.23 M) | ||||
| EBITDA | (167.16 M) | ||||
| Net Income | (211.91 M) | ||||
| Cash And Equivalents | 132.51 M | ||||
| Cash Per Share | 1.72 X | ||||
| Total Debt | 330.33 M | ||||
| Debt To Equity | 1.63 % | ||||
| Current Ratio | 1.12 X | ||||
| Book Value Per Share | 1.01 X | ||||
| Cash Flow From Operations | (235.05 M) | ||||
| Earnings Per Share | (36.00) X | ||||
| Market Capitalization | 76.9 M | ||||
| Total Asset | 619.16 M | ||||
| Retained Earnings | (4.26 B) | ||||
| Working Capital | 81.57 M | ||||
| Current Asset | 523.97 M | ||||
| Current Liabilities | 40.37 M | ||||
About Bluebird Bio Performance
By analyzing Bluebird Bio's fundamental ratios, stakeholders can gain valuable insights into Bluebird Bio's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Bluebird Bio has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Bluebird Bio has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 224.56 | 235.79 | |
| Return On Tangible Assets | (0.40) | (0.42) | |
| Return On Capital Employed | (0.67) | (0.70) | |
| Return On Assets | (0.39) | (0.41) | |
| Return On Equity | (1.25) | (1.19) |
Things to note about Bluebird bio performance evaluation
Checking the ongoing alerts about Bluebird Bio for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Bluebird bio help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Bluebird bio is way too risky over 90 days horizon | |
| Bluebird bio appears to be risky and price may revert if volatility continues | |
| Bluebird bio has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 29.5 M. Net Loss for the year was (211.91 M) with loss before overhead, payroll, taxes, and interest of (21.23 M). | |
| Bluebird bio currently holds about 132.51 M in cash with (235.05 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.72. | |
| Latest headline from businesswire.com: LE RAPPORT BLUE SHIFT DARTHUR D. LITTLE EXPLORE LIMPACT DE LIA SUR LA TRANSFORMATION DE LA RECHERCHE, DU DVELOPPEMENT ET DE LINNOVATION. |
- Analyzing Bluebird Bio's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Bluebird Bio's stock is overvalued or undervalued compared to its peers.
- Examining Bluebird Bio's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Bluebird Bio's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Bluebird Bio's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Bluebird Bio's stock. These opinions can provide insight into Bluebird Bio's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Bluebird Stock analysis
When running Bluebird Bio's price analysis, check to measure Bluebird Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bluebird Bio is operating at the current time. Most of Bluebird Bio's value examination focuses on studying past and present price action to predict the probability of Bluebird Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bluebird Bio's price. Additionally, you may evaluate how the addition of Bluebird Bio to your portfolios can decrease your overall portfolio volatility.
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges |